Company PHAXIAM Therapeutics S.A. Nasdaq
Equities
ERYP
US29604W2070
Biotechnology & Medical Research
Business Summary
Number of employees: 68
Managers
Managers | Title | Age | Since |
---|---|---|---|
Thibaut du Fayet
CEO | Chief Executive Officer | 56 | 22/06/23 |
Eric Soyer
DFI | Director of Finance/CFO | 57 | 22/06/23 |
Pascal Birman
CTO | Chief Tech/Sci/R&D Officer | - | 22/06/23 |
Cindy Fevre
CTO | Chief Tech/Sci/R&D Officer | - | 22/06/23 |
Céline Breda
CTO | Chief Tech/Sci/R&D Officer | 54 | 22/06/23 |
Karine Charton
PRN | Corporate Officer/Principal | - | 22/06/23 |
General Counsel | - | 22/06/23 | |
Human Resources Officer | - | 22/06/23 | |
Jérôme Bailly
PRN | Corporate Officer/Principal | 45 | 22/06/23 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 22/06/23 | |
Hilde Windels
BRD | Director/Board Member | 59 | 22/06/23 |
Gil Beyen
BRD | Director/Board Member | 62 | 22/06/23 |
Martine George
BRD | Director/Board Member | 76 | 22/06/23 |
Director/Board Member | 66 | 22/06/23 | |
Didier Hoch
CHM | Chairman | 68 | 22/06/23 |
Leila Nicolas
BRD | Director/Board Member | - | 22/06/23 |
Robert Sebbag
BRD | Director/Board Member | 73 | 22/06/23 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 6,075,105 | 5,597,574 ( 92.14 %) | 250 ( 0.004115 %) | 92.14 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
250 | 0.00% | 805 $ |
Company contact information
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |